Q4 2021 Results slide image

Q4 2021 Results

Participants Company overview Pharmaceuticals Financial performance CRM IHD Neuroscience Ophthalmology Respiratory & Allergy Oncology Financial review Conclusion Appendix Innovation: Pipeline overview Innovation: Clinical trials Oncology: Solid Tumors Hematology Biosimilars Global Health Abbreviations Immunology, Hepatology & Dermatology 77 Investor Relations | Q4 2021 Results NOVARTIS | Reimagining Medicine
View entire presentation